Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Comment by Noteableon Apr 07, 2023 12:32pm
173 Views
Post# 35384685

RE:RE:RE:RE:RE:RE:RE:Increase of Options from 10% to 14% of outstanding Shares

RE:RE:RE:RE:RE:RE:RE:Increase of Options from 10% to 14% of outstanding SharesThe proposed option expansion would have ONCY issuing new shares that would be set aside for managment which in fact would increase the number of fully diluted shares that have been issued from the company treasury (also known as the 'float'). The undisclosed reason that this AGM item is being put forward is because the stock  price has precipitiously fallen to a level that management's 'real value' of their share options holdings are significantly lower than before. And instead of working to increase the share price of the stock and preserve the 'real value' of their formerly issued share options, management and the Board of Directors have chosen the easy path to expand the overall number of share options available to 14% of the "float" so that management can then be granted cheap share options that would serve to 'average down' the cost of their total option holdings.

'Fully diluted shares are the total number of shares that will be outstanding, including convertible debt, warrants, restricted stock units and employee stock options. Simply put, it is the total number of shares that would result if all convertible securities had been exercised into common stock.'


https://buildd.co/funding/fully-diluted-shares  



<< Previous
Bullboard Posts
Next >>